An upfront combined strategy for endovascular haemostasis in transfemoral transcatheter aortic valve implantation

• Published in: EuroIntervention Vol. 17; no. 9; pp. 728 - 735
• Main Authors: Costa, Giuliano, Valvo, Roberto, Picci, Andrea, Criscione, Enrico, Reddavid, Claudia, Motta, Silvia, Strazzieri, Orazio, Deste, Wanda, Giuffrida, Angelo, Garretto, Valeria, Cannizzaro, Maria Teresa, Inserra, Cristina, Veroux, Pierfrancesco, Giaquinta, Alessia, Sgroi, Carmelo, Tamburino, Corrado, Barbanti, Marco
• Format: Journal Article
• Language: English
• Published: France 01.10.2021
• Subjects: Aortic Valve - diagnostic imaging; Aortic Valve - surgery; Aortic Valve Stenosis - surgery; Femoral Artery - diagnostic imaging; Femoral Artery - surgery; Hemostasis; Humans; Transcatheter Aortic Valve Replacement - adverse effects; Treatment Outcome
• ISSN: 1774-024X; 1969-6213
• DOI: 10.4244/EIJ-D-20-01125

Vascular complications still represent an important issue after transcatheter aortic valve implantation (TAVI). The aim of this study was to evaluate the effectiveness of upfront use of an adjunctive Angio-Seal (AS) plug-based system on top of suture-based devices (SBDs) for endovascular haemostasis after transfemoral (TF) TAVI. From January 2019 to April 2020, 332 consecutive patients with preprocedural computed tomography angiography (CTA) assessment underwent fully percutaneous TF-TAVI. The primary outcomes were 30-day major vascular complications and major or life-threatening (LT) bleeding due to endovascular closure system failure. A total of 246 TF-TAVI patients (123 pairs), undergoing either isolated SBD or SBD+AS, were matched using the propensity-score method. At 30 days, patients receiving SBD+AS had lower rates of major/LT bleeding (1.6% vs 8.9%, odds ratio [OR] 0.17, 95% confidence interval [CI]: 0.04-0.78; p<0.01) and major vascular complications (1.6% vs 8.9%, OR 0.17, 95% CI: 0.04-0.78; p<0.01). In addition, the use of SBD+AS was associated with a significant cost saving related to the vascular event (mean difference -315.3 € per patient, 95% CI: -566.4 € to -64.1 €; p=0.01), and a higher probability of next-day discharge (NDD) after TAVI (30.9% vs 16.3%, OR 2.30, 95% CI: 1.25-4.25; p<0.01). No difference in all-cause 30-day mortality was observed (3.3% vs 1.6% for SBD and SBD+AS groups, respectively, OR 0.49, 95% CI: 0.09-2.74; p=0.41). An upfront combined strategy with an additional AS plug-based device on top of SBDs was shown to reduce major vascular complications and major/LT bleeding due to closure system failure after TF-TAVI. This approach was associated with a cost saving and with a higher probability of NDD compared to the use of isolated SBD. Visual summary. Effectiveness of the upfront combined strategy for endovascular haemostasis in transfemoral transcatheter aortic valve implantation using Angio-Seal on top of a suture-based device (SBD) versus the isolated use of SBD. LT: life-threatening; TF-TAVI: transfemoral transcatheter aortic valve implantation.